Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Merck to Combine Keytruda and Genexine Vaccine in HPV Cancer Clinical Trial

XTALKS VITALS NEWS

Immunotherapy

The company plans to combine Keytruda with a Genexine-developed vaccine to determine whether the combo is effective against certain types of cervical cancer.

Share this!

November 18, 2016 | by Sarah Hand, M.Sc.

Merck is looking to establish even more value for its PD-L1 inhibitor immunotherapy, Keytruda. The company plans to combine Keytruda with a Genexine-developed vaccine to determine whether the combo is effective against certain types of cervical cancer.

Merck’s cancer immunotherapy drug will be combined with the biotech’s cancer vaccine, GX-188E, in a clinical trial of HPV-induced cervical cancer. Merck plans to begin with a Phase Ib/IIa clinical trial, with the possibility of expansion to a Phase III study.



The collaboration is just the latest in a long line of pair-ups among pharmaceutical and biotech companies looking to combine immunotherapy and cancer vaccines. When used as a monotherapy, Merck’s Keytruda is able to elicit a 12.5 percent response rate in advanced cervical squamous cell cancer. According to Genexine, based in South Korea, the checkpoint inhibitor drug could compliment their cancer vaccine, potentially improving response rates.

Merck and Genexine plan to start their clinical trial in early 2017, with an initial recruitment of up to 40 patients. Genexine’s GX-188E vaccine is also being developed in Phase II clinical trials of cervical intraepithelial neoplasia, as well as in a Phase I trial for HPV-associated cancers.

Merck isn’t the only pharmaceutical company looking to collaborate on these combination therapies. Bristol-Myers Squibb and AstraZeneca have combined their immunotherapy drugs with cancer vaccines from Bavarian Nordic and Inovio, respectively. Success in this space could mean the development of a blockbuster combination.


Keywords: Cancer, HPV, Immunotherapy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.